CervoMed Earnings Call Transcripts
Fiscal Year 2026
-
Significant clinical and regulatory progress was reported for a phase III-ready DLB drug, with new data supporting its targeted mechanism and clinical efficacy. Expansion into PPA and ALS indications is underway, with key biomarker and trial milestones expected later this year.
-
Neflamapimod is advancing toward a pivotal phase III trial in DLB, supported by strong phase II data, regulatory alignment, and a recent financing that extends the cash runway into 2027. The company is prioritizing a strategic partnership to fund the trial and maximize value, with additional clinical catalysts expected in PPA and ALS.
-
Significant progress was reported in developing a targeted therapy for DLB, with strong phase II results and a de-risked phase III trial set to launch by year-end. Biomarker-driven patient selection and updated manufacturing processes are expected to enhance efficacy and market potential.
Fiscal Year 2025
-
Neflamapimod is advancing to phase 3 for pure DLB, targeting a large unmet need with strong phase 2 data showing significant clinical and biomarker improvements. The upcoming 24-week trial will enroll about 300 patients, with FDA feedback expected soon.
-
A novel therapy for pure DLB patients showed significant clinical and biomarker improvements in phase 2 trials, with plans for a pivotal phase III study. The company expects FDA feedback in Q4 and will seek $50–75 million in funding for the next trial phase.
-
Sustained 32-week data from the phase IIb trial show neflamapimod significantly slows DLB progression and reduces neurodegeneration biomarkers, especially in patients without Alzheimer's co-pathology. Plans are underway for a phase III trial using the 40 mg TID dose and CDR-SB as the primary endpoint.
-
Neflamapimod, an oral drug for DLB, showed significant clinical benefits in phase IIb trials, reducing disease progression by over 50% and supporting a strong case for a single pivotal phase III trial. The DLB market is large and underserved, with high pricing potential and flexible commercialization strategies.
Fiscal Year 2024
-
A late-stage biotech is advancing an oral therapy for Dementia with Lewy Bodies, with a pivotal phase II-B trial data readout imminent. The program targets early-stage patients using a biomarker-driven approach, supported by strong prior data and industry recognition.
-
Neflamapimod, an oral CNS drug, is advancing as the leading candidate for early-stage dementia with Lewy bodies, showing promising clinical and biomarker results. The pivotal phase IIb Rewind-LB study will report top-line data in December, potentially transforming DLB treatment.
-
Significant financial and clinical milestones were achieved, including a $50 million PIPE and completion of phase IIb trial enrollment, with top-line data expected in December. Strong scientific consensus supports the drug’s mechanism in DLB, and robust IP protection is in place.
-
Neflamapimod is being advanced for early-stage DLB, targeting patients with pure cholinergic deficits and excluding those with significant tau pathology. The phase II-B REWIND-LB trial is designed for high likelihood of success, with robust biomarker and imaging strategies, and positive results could accelerate phase III initiation.